R. Barrera

发表

A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)

B. Chauffert, S. Culine, R. Janssen, 2019, Annals of Oncology.

Artificial intelligence combining radiomics and clinical data for predicting response to immunotherapy

J. Carles, E. Felip, J. Tabernero, 2019, Annals of Oncology.

Impact of germline mutations in homologous recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)

V. Conteduca, U. Giorgi, D. Lorente, 2019, Annals of Oncology.

LBA32PROREPAIR-B: A prospective cohort study of DNA repair defects in metastatic castration resistant prostate cancer (mCRPC)

P. Lapunzina, C. Pritchard, M. Vidal, 2017 .

LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361

T. Powles, A. Alva, S. Oudard, 2020 .

LBA27 Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy

J. Bellmunt, P. Maroto, M. Doménech, 2020 .

Phase II randomized study of first line avelumab with carboplatin-gemcitabine versus carboplatin-gemcitabine alone in patients with metastatic urothelial carcinoma ineligible for cisplatin-based therapy.

M. Climent, B. Mellado, J. Bellmunt, 2018 .

Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.

N. Agarwal, D. Pinato, V. Koshkin, 2023, Clinical genitourinary cancer.

Serum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra223): Results from a prospective multicentre study

I. Chirivella, O. Calvo, U. A. Herranz, 2019, Annals of Oncology.

590P PRORADIUM: Prospective analysis of the impact of germline mutations in homologous recombination (HR) genes on the response to radium-223 for metastatic castration resistant prostate cancer (mCRPC)

I. Chirivella, V. Conteduca, D. Olmos, 2021, Annals of Oncology.